Review
Open access
Aug 2026
Towards better outcomes for epidermal growth factor receptor L858R+ lung cancer patients: mutant-selective allosteric inhibitors and the potential for double-drugging.
Next-generation EGFR inhibitors with a particular focus on allosteric inhibitors developed for L858R-mutant NSCLC are surveyed, offering the possibility of double-drugging the mutant receptor to achieve deeper and more durable responses for EGFR L858R+ patients.
Michael J. Eck, David A. Scott
· Philosophical transactions o... · 1 citation